CLOs on the Move


 
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Our products are helping to address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. We are improving people’s quality of life by preventing, alleviating or curing diseases. We are helping to provide an ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.bayer.com
  • 100 Bayer Boulevard
    Whippany, NJ USA 07981
  • Phone: 862.404.3000

Executives

Name Title Contact Details
Ana Osmanovic
VP, Head of Professional and Legal Profile
Gabriel Harnier
Group General Counsel Profile
Jon Boljesic
Regional General Counsel - North America Environmental Science Profile
Karisa Cantwell
Support of General Counsel and Leadership Team - VDO Profile
Patrick Kramer
Assistant General Counsel Profile

Similar Companies

Nystrom & Associates

Nystrom & Associates Here at Nystrom & Associates, we know that you want to feel confident and excited about life. Were here to help!

Vista Pharmaceuticals

Vista Pharmaceuticals is a West Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel.

SOLESIS

Solesis is an innovative provider of biomaterials solutions and services primarily focused on the medical device and advanced therapy industries.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.